In re Inari Agriculture: Federal Circuit Denies Mandamus Over Maize Patent
Inari Agriculture sought emergency mandamus relief at the Federal Circuit in a patentability dispute involving US11659803B1, a patent covering maize inbred 1PFLQ21. The court denied the petition outright in 94 days — a swift procedural rebuff that leaves the underlying invalidity proceedings intact.
Inari’s Mandamus Bid Fails at the Federal Circuit in 94 Days
Filed on 5 September 2025 at the Court of Appeals for the Federal Circuit, Case No. 25-150 arose from a patentability or invalidity/cancellation dispute touching US11659803B1 — a patent granted to cover maize inbred 1PFLQ21, an inbred corn line. Rather than pursuing a conventional appeal, Inari Agriculture, Inc. sought a writ of mandamus, an extraordinary remedy used to compel or correct a lower tribunal’s conduct when no adequate alternative remedy exists.
On 8 December 2025, the Federal Circuit denied the petition. A mandamus denial is a procedural outcome: the appellate court declined to exercise its supervisory power over the lower tribunal, but issued no ruling on the underlying patentability merits. The underlying invalidity or cancellation proceeding — most likely before the USPTO Patent Trial and Appeal Board — is presumed to continue on its ordinary schedule.
The 94-day window from filing to denial is consistent with the Federal Circuit’s typically brisk handling of mandamus petitions, which rarely require full briefing cycles. What remains undisclosed in the public record is the precise nature of the lower-tribunal conduct Inari sought to challenge, the specific PTAB or agency proceeding at issue, and whether Inari will pursue alternative procedural vehicles. The denial suggests the Federal Circuit found no clear abuse of discretion or usurpation of power at the tribunal below.
Filing to Appeal Denied in 94 days
94-day resolution — faster than the median Federal Circuit mandamus proceeding
Mandamus denied: what the Federal Circuit’s refusal means for both parties
What a mandamus denial actually means
A writ of mandamus is an extraordinary remedy — courts grant it only when the petitioner has a clear legal right, the respondent a clear duty, and no other adequate remedy exists. Denial does not mean the petitioner’s underlying position is wrong; it means the Federal Circuit found the threshold for extraordinary intervention was not met. The lower-tribunal proceeding continues on its normal track.
No merits ruling issuedInari loses this procedural battle — but not necessarily the war
For Inari Agriculture, the denial closes this specific avenue of relief. The company must now litigate the patentability or cancellation dispute through ordinary channels — whether that means continuing before the PTAB, awaiting a final written decision, and then filing a conventional appeal. The denial offers no indication that US11659803B1 is invalid or that Inari’s substantive position is weak.
Ordinary appeal path remains openNo named respondent — proceeding remains with the lower tribunal
Because this is an In re proceeding — a single-party or agency-facing action — there is no private adverse defendant to benefit commercially from the denial. The practical beneficiary is the lower tribunal (likely the PTAB), which retains jurisdiction and can continue the invalidity or cancellation proceeding without Federal Circuit interference at this stage.
PTAB jurisdiction preservedPlant variety patent uncertainty persists for agricultural biotech
US11659803B1 remains in an unresolved patentability posture. Competitors developing inbred corn lines or products derived from similar maize germplasm should monitor the underlying PTAB proceeding closely. Until a final decision on patentability issues, freedom-to-operate assessments for maize inbred technology involving this lineage carry elevated uncertainty.
FTO uncertainty for maize inbredsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | In re: Inari Agriculture, Inc. | Company | Agricultural biotech company — holder of US11659803B1 covering maize inbred 1PFLQ21Search in Eureka ↗ |
| Defendant | Defendant | Individual | No named defendant — In re proceeding; dispute involves USPTO/PTAB patentability actionSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘the petition for a writ of mandamus is denied’ — is deliberately narrow. It forecloses this specific extraordinary-remedy avenue without adjudicating the patentability merits of US11659803B1. Appellate courts reviewing mandamus petitions apply a ‘clear and indisputable right’ standard, far stricter than the ‘substantial evidence’ or ‘de novo’ standards used in conventional appeals. The terse denial language is consistent with the Federal Circuit’s practice of issuing short orders where the threshold for mandamus is plainly not met.
US11659803B1 — Maize inbred line 1PFLQ21 plant variety patent
US11659803B1 is a US utility patent — filed under application number US17/366126 — covering the maize inbred designated 1PFLQ21. Inbred line patents in corn protect specific homozygous germplasm developed through successive self-pollination, conferring exclusive rights over the production, sale, and use of seeds of that specific genetic composition. Such patents are central to commercial hybrid seed development, where the inbred parent lines are the core proprietary asset.
For Inari Agriculture — a company focused on seed improvement through gene editing and breeding — maintaining patent protection over proprietary inbred lines is strategically critical. A successful invalidity challenge to US11659803B1 at the PTAB could expose the underlying germplasm to free use by competitors, disrupting licensing programmes and hybrid seed commercialisation. The pending patentability proceeding makes this patent a high-priority monitoring target for any company active in commercial corn breeding or trait integration.
Should you run an FTO analysis against US11659803B1?
Any seed company, agricultural biotech firm, or breeding programme working with maize inbred germplasm — particularly lines phenotypically or genotypically related to 1PFLQ21 — should assess freedom to operate against US11659803B1 before advancing products toward commercialisation. The patent’s patentability status is actively contested, but it remains in force during PTAB proceedings. Relying on the pending challenge as a passive FTO shield carries commercial risk.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US11659803B1 against your own germplasm descriptors and breeding records, flag prior art cited in the PTAB proceeding, and surface related plant patent families in the Inari Agriculture portfolio. This enables R&D and IP teams to make informed go/no-go decisions on inbred line development programmes before the PTAB issues its final written decision.
Run a freedom-to-operate analysis on US11659803B1 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit mandamus and plant patent patentability cases
Explore Federal Circuit mandamus petitions and PTAB patentability challenges involving agricultural biotech and plant variety patents in similar technology domains.
What this case signals for agricultural biotech plant patent strategy
Mandamus is a high-risk, rarely granted tool. Inari’s attempt — and its swift denial — carries lessons for any biotech team facing PTAB proceedings.
Mandamus is not a shortcut through PTAB: plan for the full appeal path
Inari’s petition was denied in 94 days, leaving the underlying patentability dispute unresolved. IP teams facing adverse PTAB proceedings should treat mandamus as a narrow emergency tool, not a strategic bypass. Build timelines around the conventional appeal route: final written decision, then Federal Circuit appeal under 35 U.S.C. § 141.
Plant variety patents face prolonged uncertainty during PTAB review
With US11659803B1 in an unresolved patentability posture, any product or breeding program touching maize inbred 1PFLQ21 germplasm carries licensing and FTO risk. Competitors should conduct landscape searches now — before the PTAB issues a final written decision that could either validate or cancel the patent.
In v Defendant — key questions answered
The Federal Circuit denied Inari Agriculture’s petition for a writ of mandamus on 8 December 2025. The denial is procedural — the court declined to intervene in the lower-tribunal proceeding — and does not constitute a ruling on the patentability merits of US11659803B1, which covers maize inbred 1PFLQ21.
A writ of mandamus is an extraordinary appellate remedy compelling a lower court or agency to perform a duty or correct a clear legal error. Petitioners must show a clear and indisputable right to relief and the absence of any adequate alternative remedy. The public record does not disclose the specific PTAB conduct Inari sought to challenge, but the vehicle suggests Inari believed ordinary appeal channels were inadequate at that stage.
US11659803B1 remains in force and the underlying patentability or cancellation proceeding — most likely at the PTAB — continues on its ordinary schedule. Inari can pursue a conventional Federal Circuit appeal once the PTAB issues a final written decision. The patent’s enforceability is not affected by the mandamus denial itself.
Maize inbred 1PFLQ21 is a specific homozygous corn line covered by US11659803B1. Inbred lines are the proprietary parent lines used to produce commercial hybrid seed — the dominant format for corn production globally. Patent protection over an inbred line gives the holder exclusive rights to use that germplasm in hybrid seed programmes, making it a high-value commercial asset in the seed industry.
No. The denial is purely procedural and carries no implication about the validity or invalidity of US11659803B1. The Federal Circuit simply found that the threshold for extraordinary mandamus relief was not met at this stage. Patentability will be determined through the underlying PTAB proceeding, with any dissatisfied party retaining the right to appeal a final written decision to the Federal Circuit.
PatSnap Eureka searches patents and litigation data to answer instantly.